Skip to content
GLP-1 Savers
Menu

Head-to-head · Value Score

Alan Meds vs Revel RX

Two GLP-1 deals, scored on the same six factors. Alan Meds lands a Value Score of 90, Revel RX a 80. Here's who gives you the honest lower price — and where each one bites back.

★ Better value

Alan Meds

#7 · Grade A · Best Value

Est. first month

$99/mo

Save ~93% vs brand-name
Get this deal Full Alan Meds review →
VS

Revel RX

#68 · Grade B · Good Value

Est. first month

From $89/mo (all doses, compounded)

Save ~93% vs brand-name
Get this deal Full Revel RX review →

The verdict

Better value: Alan Meds

Alan Meds takes it on Value Score, 90 to 80 an est. $99/mo first month, with no teaser step-up baked in. Revel RX isn't out of it: Shoppers who want flat-rate compounded GLP-1 from $89/mo with LegitScript-verified telehealth care.

Our #1 overall:Neither of these is our top pick — that's CoreAge Rx (Value Score 93).See why →

Deal-by-deal

The numbers that decide it. Green ✓ marks the stronger side on each line.

DealAlan MedsRevel RX
Value Score90 (A)80 (B)
Est. first month$99/moFrom $89/mo (all doses, compounded)
Save vs brand-name~93%~93%
Semaglutide$99/moFrom $89/mo (all doses, compounded)
Tirzepatide$145/moFrom $155/mo (all doses, compounded)
Both moleculesYesYes
PricingFlat — no step-upFlat — no step-up
CoverageAll 50 statesCoverage not published

Factor by factor

The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.

95
Lowest Real Price
90
Alan Meds: 95. Revel RX: 90.
85
No Teaser-Rate Bait
90
Alan Meds: 85. Revel RX: 90.
98
Nationwide Availability
45
Alan Meds: 98. Revel RX: 45.
94
Both Molecules
92
Alan Meds: 94. Revel RX: 92.
82
Easy Cancellation
58
Alan Meds: 82. Revel RX: 58.
72
Reputation
78
Alan Meds: 72. Revel RX: 78.

Alan Meds

Double-digit semaglutide ($99) and a $145 tirzepatide, both nationwide, with an oral route for the needle-shy.

Why it's a deal

  • $99 flat semaglutide and a low $145 tirzepatide
  • Available in all 50 states
  • Offers an oral/sublingual route

The fine print

  • Not LegitScript-certified — do your own pharmacy diligence
  • Newer operator with a thin public track record

Revel RX

Revel RX is a Michigan-based telehealth weight-loss platform offering compounded semaglutide at $89/month and compounded tirzepatide at $155/month — flat-rate at every dose tier.

Why it's a deal

  • Industry-low flat pricing: $89/mo for compounded semaglutide and $155/mo for tirzepatide at every dose
  • LegitScript verified and BBB accredited with an A+ rating — above-average trust signals for a compounded platform
  • Named pharmacy partners: Manifest Pharmacy and Red Rock Home Pharmacy (503A + 503B facilities)
  • Free overnight cold shipping included; no hidden fees or dose-based price increases
  • Clinical review by MD Integrations, an independent medical group, before any prescription is issued

The fine print

  • States served are not publicly listed; eligible states requires completing intake to confirm coverage
  • No labs, coaching, or ongoing health support disclosed in any public materials
  • Compounded medications are not FDA-approved (site discloses this)
  • Newer brand with limited public patient reviews or Trustpilot rating
  • Pharmacy partners named but no accreditation details (PCAB, 503B cGMP) published on the site
Get the Alan Meds deal Get the Revel RX deal

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.

Neither one the right fit? Every program that outscores Alan Meds is ranked on the Alan Meds alternatives board, and the same list for the other side is on alternatives to Revel RX.

More head-to-heads

← All comparisons

Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.